{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:19:31Z","timestamp":1794028771504,"version":"4.8.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The apolipoprotein E (\n                      <jats:italic>APOE<\/jats:italic>\n                      ) \u03b54 allele confers the strongest risk for late-onset Alzheimer\u2019s disease (AD) besides age itself, but the mechanisms underlying this risk are debated. One hypothesis supported by evidence from multiple labs is that apoE4 binds to the amyloid-\u03b2 (A\u03b2) peptide and catalyzes its polymerization into neurotoxic oligomers and fibrils. Inhibiting this early step in the amyloid cascade may thereby reduce or prevent neurodegeneration and AD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a design of experiments (DOE) approach, we developed a high-throughput assay to identify inhibitors of apoE4-catalyzed polymerization of A\u03b2 into oligomers and fibrils. We used it to screen the NIH Clinical Collection of small molecule drugs tested previously in human clinical trials. We then evaluated the efficacy and cytotoxicity of the hit compounds in primary neuron models of apoE4-induced A\u03b2 and phosphorylated tau aggregation. Finally, we performed retrospective analyses of the National Alzheimer\u2019s Coordinating Center (NACC) clinical dataset, using Cox regression and Cox proportional hazards models to determine if the use of two FDA-approved hit compounds was associated with better cognitive scores (Mini-Mental State Exam), or improved AD clinical diagnosis, when compared with other medications of the same clinical indication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our high-throughput screen identified eight blood-brain barrier (BBB)-permeable hit compounds that reduced apoE4-catalyzed A\u03b2 oligomer and fibril formation in a dose-dependent manner. Five hit compounds were non-toxic toward cultured neurons and also reduced apoE4-promoted A\u03b2 and tau neuropathology in a dose-dependent manner. Three of the five compounds were determined to be specific inhibitors of apoE4, whereas the other two compounds were A\u03b2 or tau aggregation inhibitors. When prescribed to AD patients for their normal clinical indications, two of the apoE4 inhibitors, imipramine and olanzapine, but not other (non-hit) antipsychotic or antidepressant medications, were associated with improvements in cognition and clinical diagnosis, especially among\n                      <jats:italic>APOE4<\/jats:italic>\n                      carriers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The critical test of any proposed AD mechanism is whether it leads to effective treatments. Our high-throughput screen identified two promising FDA-approved drugs, imipramine and olanzapine, which have no structural, functional, or clinical similarities other than their shared ability to inhibit apoE4-catalyzed A\u03b2 polymerization, thus identifying this mechanism as an essential contribution of apoE4 to AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-022-01020-9","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T03:07:05Z","timestamp":1656472025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Imipramine and olanzapine block apoE4-catalyzed polymerization of A\u03b2 and show evidence of improving Alzheimer\u2019s disease cognition"],"prefix":"10.1186","volume":"14","author":[{"given":"Noah R.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena C.-J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sillau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Lucero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Viltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Markham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Ranjitha","family":"Dhanasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Chial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huntington","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133.","journal-title":"Science."},{"issue":"Pt 4","key":"1020_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1046\/j.1469-1809.1999.6340301.x","volume":"63","author":"RM Corbo","year":"1999","unstructured":"Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a \u2018thrifty\u2019 allele? Ann Hum Genet. 1999;63(Pt 4):301\u201310.","journal-title":"Ann Hum Genet"},{"issue":"8","key":"1020_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1056\/NEJM199802193380804","volume":"338","author":"R Mayeux","year":"1998","unstructured":"Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer\u2019s disease. Alzheimer's disease centers consortium on Apolipoprotein E and Alzheimer's disease. N Engl J Med. 1998;338(8):506\u201311.","journal-title":"N Engl J Med"},{"issue":"19","key":"1020_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1056\/NEJM199511093331902","volume":"333","author":"T Polvikoski","year":"1995","unstructured":"Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333(19):1242\u20137.","journal-title":"N Engl J Med"},{"issue":"7806","key":"1020_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71\u20136.","journal-title":"Nature."},{"key":"1020_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/372092a0","volume":"372","author":"J Ma","year":"1994","unstructured":"Ma J, Yee A, Brewer HB Jr, Das S, Potter H. Amyloid-associated proteins a1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer \u00df-protein into filaments. Nature. 1994;372:92\u20134.","journal-title":"Nature."},{"key":"1020_CR7","first-page":"1030","volume":"145","author":"T Wisniewski","year":"1994","unstructured":"Wisniewski T, Casta\u00f1o EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer\u2019s fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030\u20135.","journal-title":"Am J Pathol"},{"issue":"2","key":"1020_CR8","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1172\/JCI117407","volume":"94","author":"DA Sanan","year":"1994","unstructured":"Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer\u2019s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994;94(2):860\u20139.","journal-title":"J Clin Invest"},{"issue":"Pt 2","key":"1020_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1042\/bj3060599","volume":"306","author":"EM Castano","year":"1995","unstructured":"Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, et al. Fibrillogenesis in Alzheimer\u2019s disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995;306(Pt 2):599\u2013604.","journal-title":"Biochem J"},{"issue":"43","key":"1020_CR10","doi-asserted-by":"publisher","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","volume":"32","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci. 2012;32(43):15181\u201392.","journal-title":"J Neurosci"},{"issue":"5","key":"1020_CR11","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1096\/fj.10-175976","volume":"25","author":"E Cerf","year":"2011","unstructured":"Cerf E, Gustot A, Goormaghtigh E, Ruysschaert JM, Raussens V. High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J. 2011;25(5):1585\u201395.","journal-title":"FASEB J"},{"key":"1020_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/0197-4580(96)00112-1","volume":"17","author":"J Ma","year":"1996","unstructured":"Ma J, Brewer HB Jr, Potter H. Alzheimer A\u03b2 neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A\u03b2-related peptides. Neurobiol Aging. 1996;17:773\u201380.","journal-title":"Neurobiol Aging"},{"issue":"Pt 7","key":"1020_CR13","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/brain\/aws127","volume":"135","author":"RM Koffie","year":"2012","unstructured":"Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, et al. Apolipoprotein E4 effects in Alzheimer\u2019s disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain. 2012;135(Pt 7):2155\u201368.","journal-title":"Brain."},{"issue":"8","key":"1020_CR14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.neurobiolaging.2006.05.024","volume":"28","author":"AM Manelli","year":"2007","unstructured":"Manelli AM, Bulfinch LC, Sullivan PM, LaDu MJ. Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging. 2007;28(8):1139\u201347.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"1020_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","volume":"96","author":"CC Liu","year":"2017","unstructured":"Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96(5):1024\u201332 e3.","journal-title":"Neuron."},{"key":"1020_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1749-6632.2000.tb06919.x","volume":"920","author":"MC Irizarry","year":"2000","unstructured":"Irizarry MC, Rebeck GW, Cheung B, Bales K, Paul SM, Holzman D, et al. Modulation of a beta deposition in APP transgenic mice by an apolipoprotein E null background. Ann N Y Acad Sci. 2000;920:171\u20138.","journal-title":"Ann N Y Acad Sci"},{"issue":"26","key":"1020_CR17","doi-asserted-by":"publisher","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","volume":"96","author":"KR Bales","year":"1999","unstructured":"Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96(26):15233\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1020_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jamaneurol.2017.4325","volume":"75","author":"YY Lim","year":"2018","unstructured":"Lim YY, Kalinowski P, Pietrzak RH, Laws SM, Burnham SC, Ames D, et al. Association of beta-amyloid and apolipoprotein E epsilon 4 with memory decline in preclinical Alzheimer disease. Jama Neurol. 2018;75(4):488\u201394.","journal-title":"Jama Neurol"},{"key":"1020_CR19","doi-asserted-by":"crossref","unstructured":"Aoyagi A, Condello C, Stohr J, Yue W, Rivera BM, Lee JC, et al. Abeta and tau prion-like activities decline with longevity in the Alzheimer\u2019s disease human brain. Sci Transl Med. 2019;11(490):eaat8462.","DOI":"10.1126\/scitranslmed.aat8462"},{"issue":"8","key":"1020_CR20","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","volume":"288","author":"LM Tai","year":"2013","unstructured":"Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E\/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013;288(8):5914\u201326.","journal-title":"J Biol Chem"},{"key":"1020_CR21","doi-asserted-by":"publisher","first-page":"104795","DOI":"10.1016\/j.nbd.2020.104795","volume":"138","author":"DA Butterfield","year":"2020","unstructured":"Butterfield DA, Mattson MP. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer\u2019s disease. Neurobiol Dis. 2020;138:104795.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"1020_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.conb.2011.08.002","volume":"21","author":"CD Keene","year":"2011","unstructured":"Keene CD, Cudaback E, Li X, Montine KS, Montine TJ. Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer\u2019s disease. Curr Opin Neurobiol. 2011;21(6):920\u20138.","journal-title":"Curr Opin Neurobiol"},{"issue":"5","key":"1020_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1194\/jlr.R075481","volume":"58","author":"TV Huynh","year":"2017","unstructured":"Huynh TV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer\u2019s disease: the influence of apolipoprotein E on amyloid-beta and other amyloidogenic proteins. J Lipid Res. 2017;58(5):824\u201336.","journal-title":"J Lipid Res"},{"issue":"1","key":"1020_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer\u2019s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163\u20136.","journal-title":"Brain Res"},{"key":"1020_CR25","doi-asserted-by":"crossref","unstructured":"Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, Zou F, et al. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:Article 11.","DOI":"10.1186\/1750-1326-9-11"},{"issue":"11","key":"1020_CR26","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680\u20133.","journal-title":"Nat Med"},{"issue":"5","key":"1020_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","volume":"96","author":"TV Huynh","year":"2017","unstructured":"Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of beta-amyloidosis. Neuron. 2017;96(5):1013\u201323 e4.","journal-title":"Neuron."},{"issue":"1","key":"1020_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-022-00516-0","volume":"17","author":"TE Mahan","year":"2022","unstructured":"Mahan TE, Wang C, Bao X, Choudhury A, Ulrich JD, Holtzman DM. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Abeta accumulation and plaque-related pathology in a mouse model of amyloidosis. Mol Neurodegener. 2022;17(1):13.","journal-title":"Mol Neurodegener"},{"key":"1020_CR29","doi-asserted-by":"crossref","unstructured":"Xiong M, Jiang H, Serrano JR, Gonzales ER, Wang C, Gratuze M, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. 2021;13(581):eabd7522.","DOI":"10.1126\/scitranslmed.abd7522"},{"issue":"s1","key":"1020_CR30","doi-asserted-by":"publisher","first-page":"S299","DOI":"10.3233\/JAD-179909","volume":"64","author":"E Drummond","year":"2018","unstructured":"Drummond E, Goni F, Liu S, Prelli F, Scholtzova H, Wisniewski T. Potential novel approaches to understand the pathogenesis and treat Alzheimer\u2019s disease. J Alzheimers Dis. 2018;64(s1):S299\u2013312.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1020_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","volume":"24","author":"C Wang","year":"2018","unstructured":"Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med. 2018;24(5):647\u201357.","journal-title":"Nat Med"},{"issue":"19","key":"1020_CR32","doi-asserted-by":"publisher","first-page":"17217","DOI":"10.1074\/jbc.M110.217380","volume":"286","author":"J Brodbeck","year":"2011","unstructured":"Brodbeck J, McGuire J, Liu Z, Meyer-Franke A, Balestra ME, Jeong DE, et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J Biol Chem. 2011;286(19):17217\u201326.","journal-title":"J Biol Chem"},{"issue":"3","key":"1020_CR33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0002-9440(10)63355-X","volume":"165","author":"M Sadowski","year":"2004","unstructured":"Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, et al. A synthetic peptide blocking the apolipoprotein E\/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol. 2004;165(3):937\u201348.","journal-title":"Am J Pathol"},{"issue":"1","key":"1020_CR34","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1038\/s41598-017-08604-8","volume":"7","author":"S Liu","year":"2017","unstructured":"Liu S, Park S, Allington G, Prelli F, Sun Y, Marta-Ariza M, et al. Targeting apolipoprotein E\/amyloid beta binding by peptoid CPO_Abeta17-21 P ameliorates Alzheimer\u2019s disease related pathology and cognitive decline. Sci Rep. 2017;7(1):8009.","journal-title":"Sci Rep"},{"issue":"3","key":"1020_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/13506120009146831","volume":"7","author":"Y Fezoui","year":"2000","unstructured":"Fezoui Y, Hartley DM, Harper JD, Khurana R, Walsh DM, Condron MM, et al. An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid. 2000;7(3):166\u201378.","journal-title":"Amyloid."},{"issue":"4","key":"1020_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0022-2836(92)90106-T","volume":"225","author":"CJ Barrow","year":"1992","unstructured":"Barrow CJ, Yasuda A, Kenny PT, Zagorski MG. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer\u2019s disease. Analysis of circular dichroism spectra. J Mol Biol. 1992;225(4):1075\u201393.","journal-title":"J Mol Biol"},{"key":"1020_CR37","doi-asserted-by":"publisher","first-page":"80ps16","DOI":"10.1126\/scitranslmed.3001862","volume":"3","author":"R Huang","year":"2011","unstructured":"Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011;3:80ps16.","journal-title":"Sci Transl Med"},{"issue":"40","key":"1020_CR38","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129\u201340.","journal-title":"J Neurosci"},{"issue":"15","key":"1020_CR39","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1523\/JNEUROSCI.3672-12.2013","volume":"33","author":"RM Cohen","year":"2013","unstructured":"Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci. 2013;33(15):6245\u201356.","journal-title":"J Neurosci"},{"issue":"3","key":"1020_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/WAD.0b013e318142774e","volume":"21","author":"DL Beekly","year":"2007","unstructured":"Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, et al. The National Alzheimer\u2019s coordinating center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord. 2007;21(3):249\u201358.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1020_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-60761-744-0_2","volume":"670","author":"WB Stine","year":"2011","unstructured":"Stine WB, Jungbauer L, Yu C, LaDu MJ. Preparing synthetic Abeta in different aggregation states. Methods Mol Biol. 2011;670:13\u201332.","journal-title":"Methods Mol Biol"},{"issue":"38","key":"1020_CR42","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1523\/JNEUROSCI.1521-05.2005","volume":"25","author":"K Rezai-Zadeh","year":"2005","unstructured":"Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 2005;25(38):8807\u201314.","journal-title":"J Neurosci"},{"issue":"5054","key":"1020_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135.","journal-title":"Science."},{"issue":"3","key":"1020_CR44","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3233\/JAD-180780","volume":"69","author":"RJ Elsworthy","year":"2019","unstructured":"Elsworthy RJ, Aldred S. Depression in Alzheimer\u2019s disease: an alternative role for selective serotonin reuptake inhibitors? J Alzheimers Dis. 2019;69(3):651\u201361.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1020_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/1673-5374.264445","volume":"15","author":"B Mdawar","year":"2020","unstructured":"Mdawar B, Ghossoub E, Khoury R. Selective serotonin reuptake inhibitors and Alzheimer\u2019s disease. Neural Regen Res. 2020;15(1):41\u20136.","journal-title":"Neural Regen Res"},{"issue":"7","key":"1020_CR46","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.bbapap.2010.04.001","volume":"1804","author":"M Biancalana","year":"2010","unstructured":"Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010;1804(7):1405\u201312.","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"1020_CR47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1212\/WNL.0b013e318211c352","volume":"76","author":"VB Gupta","year":"2011","unstructured":"Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011;76(12):1091\u20138.","journal-title":"Neurology."},{"issue":"20","key":"1020_CR48","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1093\/hmg\/dds296","volume":"21","author":"C Cruchaga","year":"2012","unstructured":"Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer\u2019s disease. Hum Mol Genet. 2012;21(20):4558\u201371.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1020_CR49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-013-1086-9","volume":"125","author":"M Shinohara","year":"2013","unstructured":"Shinohara M, Petersen RC, Dickson DW, Bu G. Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol. 2013;125(4):535\u201347.","journal-title":"Acta Neuropathol"},{"key":"1020_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1750-1326-8-13","volume":"8","author":"JD Ulrich","year":"2013","unstructured":"Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 2013;8:13.","journal-title":"Mol Neurodegener"},{"issue":"50","key":"1020_CR51","doi-asserted-by":"publisher","first-page":"41774","DOI":"10.1074\/jbc.M112.407957","volume":"287","author":"KL Youmans","year":"2012","unstructured":"Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287(50):41774\u201386.","journal-title":"J Biol Chem"},{"issue":"17","key":"1020_CR52","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(17):8098\u2013102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"1020_CR53","doi-asserted-by":"publisher","first-page":"10602","DOI":"10.1074\/jbc.271.18.10602","volume":"271","author":"AA Golabek","year":"1996","unstructured":"Golabek AA, Soto C, Vogel T, Wisniewski T. The interaction between apolipoprotein E and Alzheimer\u2019s amyloid beta-peptide is dependent on beta-peptide conformation. J Biol Chem. 1996;271(18):10602\u20136.","journal-title":"J Biol Chem"},{"key":"1020_CR54","first-page":"489428","volume":"2012","author":"H Potter","year":"2012","unstructured":"Potter H, Wisniewski T. Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade. Int J Alzheimers Dis. 2012;2012:489428.","journal-title":"Int J Alzheimers Dis"},{"issue":"1","key":"1020_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/(SICI)1097-4547(19961001)46:1<58::AID-JNR8>3.0.CO;2-E","volume":"46","author":"S Webster","year":"1996","unstructured":"Webster S, Rogers J. Relative efficacies of amyloid beta peptide (a beta) binding proteins in a beta aggregation. J Neurosci Res. 1996;46(1):58\u201366.","journal-title":"J Neurosci Res"},{"issue":"51","key":"1020_CR56","doi-asserted-by":"publisher","first-page":"18694","DOI":"10.1073\/pnas.0508254102","volume":"102","author":"S Chang","year":"2005","unstructured":"Chang S, Ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A. 2005;102(51):18694\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"53","key":"1020_CR57","doi-asserted-by":"publisher","first-page":"44593","DOI":"10.1074\/jbc.M112.420224","volume":"287","author":"J Li","year":"2012","unstructured":"Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, et al. Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem. 2012;287(53):44593\u2013601.","journal-title":"J Biol Chem"},{"issue":"19","key":"1020_CR58","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1523\/JNEUROSCI.5476-05.2006","volume":"26","author":"Q Xu","year":"2006","unstructured":"Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006;26(19):4985\u201394.","journal-title":"J Neurosci"},{"key":"1020_CR59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1020_CR60","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971\u201382.","journal-title":"Neuron."},{"issue":"2","key":"1020_CR61","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1124\/jpet.109.162164","volume":"332","author":"F Chavant","year":"2010","unstructured":"Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, et al. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer\u2019s disease. J Pharmacol Exp Ther. 2010;332(2):505\u201314.","journal-title":"J Pharmacol Exp Ther"},{"key":"1020_CR62","doi-asserted-by":"publisher","first-page":"113260","DOI":"10.1016\/j.bbr.2021.113260","volume":"408","author":"P Javadpour","year":"2021","unstructured":"Javadpour P, Askari S, Rashidi FS, Dargahi L, Ahmadiani A, Ghasemi R. Imipramine alleviates memory impairment and hippocampal apoptosis in STZ-induced sporadic Alzheimer\u2019s rat model: possible contribution of MAPKs and insulin signaling. Behav Brain Res. 2021;408:113260.","journal-title":"Behav Brain Res"},{"issue":"12","key":"1020_CR63","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.bbadis.2013.07.022","volume":"1832","author":"S Wuwongse","year":"2013","unstructured":"Wuwongse S, Cheng SS, Wong GT, Hung CH, Zhang NQ, Ho YS, et al. Effects of corticosterone and amyloid-beta on proteins essential for synaptic function: implications for depression and Alzheimer\u2019s disease. Biochim Biophys Acta. 2013;1832(12):2245\u201356.","journal-title":"Biochim Biophys Acta"},{"issue":"15","key":"1020_CR64","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med. 2006;355(15):1525\u201338.","journal-title":"N Engl J Med"},{"issue":"4","key":"1020_CR65","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/jnr.20570","volume":"81","author":"H Wang","year":"2005","unstructured":"Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res. 2005;81(4):572\u201380.","journal-title":"J Neurosci Res"},{"issue":"3","key":"1020_CR66","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00213-011-2291-7","volume":"217","author":"MC Yang","year":"2011","unstructured":"Yang MC, Lung FW. Neuroprotection of paliperidone on SH-SY5Y cells against beta-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology. 2011;217(3):397\u2013410.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1020_CR67","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.nbd.2010.03.022","volume":"39","author":"Y Ding","year":"2010","unstructured":"Ding Y, Qiao A, Fan GH. Indirubin-3\u2032-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2010;39(2):156\u201368.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1020_CR68","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-019-0337-1","volume":"14","author":"TV Huynh","year":"2019","unstructured":"Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, et al. Lack of hepatic apoE does not influence early Abeta deposition: observations from a new APOE knock-in model. Mol Neurodegener. 2019;14(1):37.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1020_CR69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3727\/194982412X13462021398010","volume":"14","author":"LN Nilsson","year":"2012","unstructured":"Nilsson LN, Gografe S, Costa DA, Hughes T, Dressler D, Potter H. Use of fused circulations to investigate the role of apolipoprotein E as amyloid catalyst and peripheral sink in Alzheimer\u2019s disease. Technol Innov. 2012;14(2):199\u2013208.","journal-title":"Technol Innov"},{"issue":"236","key":"1020_CR70","doi-asserted-by":"publisher","first-page":"236re4","DOI":"10.1126\/scitranslmed.3008169","volume":"6","author":"YI Sheline","year":"2014","unstructured":"Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6(236):236re4.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1020_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1176\/ajp.146.1.45","volume":"146","author":"BV Reifler","year":"1989","unstructured":"Reifler BV, Teri L, Raskind M, Veith R, Barnes R, White E, et al. Double-blind trial of imipramine in Alzheimer\u2019s disease patients with and without depression. Am J Psychiatry. 1989;146(1):45\u20139.","journal-title":"Am J Psychiatry"},{"issue":"15","key":"1020_CR72","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u201343.","journal-title":"JAMA."},{"issue":"8","key":"1020_CR73","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673\u201383.","journal-title":"Nat Rev Drug Discov"},{"key":"1020_CR74","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042915-103753","volume":"68","author":"WV Graham","year":"2017","unstructured":"Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer\u2019s disease therapy and prevention strategies. Annu Rev Med. 2017;68:413\u201330.","journal-title":"Annu Rev Med"},{"issue":"40","key":"1020_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1021\/cen-09040-cover","volume":"90","author":"A Thayer","year":"2012","unstructured":"Thayer A. Drug repurposing. Chem Eng News. 2012;90(40):15\u201325.","journal-title":"Chem Eng News"},{"issue":"1","key":"1020_CR76","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1602\/neurorx.1.1.101","volume":"1","author":"SA Lipton","year":"2004","unstructured":"Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004;1(1):101\u201310.","journal-title":"NeuroRx."},{"key":"1020_CR77","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.mcn.2016.07.001","volume":"80","author":"DJ Cooper","year":"2017","unstructured":"Cooper DJ, Zunino G, Bixby JL, Lemmon VP. Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration. Mol Cell Neurosci. 2017;80:161\u20139.","journal-title":"Mol Cell Neurosci"},{"issue":"Pt 2","key":"1020_CR78","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1042\/bj3480359","volume":"348","author":"T Tokuda","year":"2000","unstructured":"Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer\u2019s amyloid beta peptides. Biochem J. 2000;348(Pt 2):359\u201365.","journal-title":"Biochem J"},{"issue":"9","key":"1020_CR79","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501\u201318.","journal-title":"Nat Rev Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01020-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01020-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01020-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T04:10:45Z","timestamp":1656475845000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01020-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01020-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1428873\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mice and rats were treated in accordance with the <i>Guide for the Care and Use of Laboratory Animals<\/i>. All procedures were approved by the Institutional Animal Care and Use Committee of the University of Colorado (Animal Welfare Assurance # D16-00171.As determined by the University of Washington Human Subjects Division, the NACC database itself is exempt from institutional review board review and approval because it does not involve human subjects, as defined by federal and state regulations. However, all contributing ADRCs are required to obtain informed consent from their participants and to maintain their own separate institutional review board review and approval from their institution prior to submitting data to NACC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}